ARIAD to Host Investor Conference Call With Senior Management On October 26, 2000 At 4:15 PM EDT.Business Editors/Medical Writers CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 24, 2000 ARIAD ARIAD Allison Research Index of Art and Design Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that it will be hosting an investor conference call on Thursday, October 26, 2000 at 4:15 p.m. EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT , to discuss ongoing progress in the development of the Company's lead product candidates, recent results of in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. studies with its dual-action osteoporosis drug, and third-quarter financial results. Harvey J. Berger, M.D., chairman and chief executive officer, and Jay LaMarche, executive vice president and chief financial officer, will participate on the conference call. There will a question and answer period following introductory remarks by Dr. Berger. The call-in number for United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. participants is 1-800-260-0702; international participants may call 303-446-0284. The event will be simultaneously Webcast via Vcall and may be accessed at http://www.vcall.com/NASApp/VCall/EventPage?ID=48783 at the time of the call. For those unable to participate, a digitized replay of the call will be available beginning at 7:45 p.m. on October 26, 2000 until midnight, November 2, 2000 by calling 1-800-475-6701 in the United States and 320-365-3844 internationally; the access code for replay is 545202. The Webcast will also be archived on Vcall for thirty days beginning one hour after the conference call ends at http://www.vcall.com/NASApp/VCall/EventPage?ID=48783. ARIAD Pharmaceuticals, Inc. (www.ariad.com) is a leader in the discovery and development of gene therapy, cell therapy, stem cell therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs and protein therapy products featuring dose-dependent regulation by small-molecule drugs, as well as small-molecule inhibitors of signal transduction Signal transduction The transmission of molecular signals from a cell's exterior to its interior. Molecular signals are transmitted between cells by the secretion of hormones and other chemical factors, which are then picked up by different cells. . Some of the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, which include, but are not limited to, risks and uncertainties regarding the Company's preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. , the ability of the Company to conduct clinical trials of its products and the results of such trials, as well as risks and uncertainties relating to economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on our collaborators and other factors under the heading "Cautionary Statement Regarding Forward-Looking Statements" in ARIAD's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended December 31, 1999 filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion